An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced that CEO Joseph Payne will participate in the "RNA Therapeutics in Rare Diseases" panel at the Cantor Fitzgerald Virtual Rare Disease Summit on March 29, 2022, at 2:45 p.m. ET. This event highlights Arcturus' commitment to RNA medicines, particularly in infectious disease vaccines and rare liver and respiratory diseases. The company, based in San Diego, has a diverse pipeline of mRNA vaccine programs, including those for COVID-19 and cystic fibrosis, supported by innovative delivery technologies and strategic partnerships.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President and CEO of Arcturus Therapeutics, will participate in a panel discussion titled “RNA Therapeutics in Rare Diseases” at the Cantor Fitzgerald Virtual rare Disease Summit on Barclays Global Healthcare Conference on Tuesday, March 29, 2022 at 2:45 p.m. ET.
Those interested in participating in the Cantor Fitzgerald Virtual Rare Disease Summit are encouraged to contact their Cantor Fitzgerald representative.
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, hepatitis B virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.
IR and Media Contact:
Deepankar Roy, Ph.D.
Senior Director, Investor Relations, Public Relations & Marketing
(858) 900-2682
IR@ArcturusRx.com
Source: Arcturus Therapeutics Holdings Inc.
FAQ
When is Arcturus Therapeutics participating in the Cantor Fitzgerald Virtual Rare Disease Summit?
Arcturus Therapeutics will participate in the Cantor Fitzgerald Virtual Rare Disease Summit on March 29, 2022, at 2:45 p.m. ET.
Who is representing Arcturus Therapeutics at the RNA Therapeutics panel?
Joseph Payne, the President and CEO, will represent Arcturus Therapeutics at the panel discussion.
What is the focus of Arcturus Therapeutics' research?
Arcturus Therapeutics focuses on RNA medicines and vaccines, particularly for infectious diseases and rare diseases affecting the liver and respiratory systems.
What technologies does Arcturus Therapeutics utilize in its mRNA programs?
Arcturus uses LUNAR® lipid-mediated delivery and STARR™ mRNA Technology for its mRNA vaccine programs.
What vaccine programs are in Arcturus Therapeutics' pipeline?
Arcturus has mRNA vaccine programs for COVID-19, influenza, and treatments for conditions like cystic fibrosis and ornithine transcarbamylase deficiency.
